Navigation Links
Vermillion Announces Return of Eric Fung, M.D., Ph.D.
Date:10/2/2009

FREMONT, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Vermillion, Inc (OTC: VRMLQ.PK) today announced that Eric Fung, M.D., Ph.D., has rejoined the company to become its Chief Science Officer. This position will be formally held by Dr. Fung upon the completion of the Company's restructuring and reorganization under Chapter 11 of the U.S. Bankruptcy Code or earlier, if deemed appropriate by Vermillion's Board of Directors. In the interim, Dr. Fung will work as an independent consultant.

"Dr. Fung was instrumental in the development of the OVA1(TM) test, including biomarker discovery to validation, design and execution of the clinical trial, and submission to the FDA," said Gail Page, Executive Director of the Company. "We are pleased to welcome him back to Vermillion, where he will play a key role in commercialization of the OVA1 test as well as further development of other potential tests in Vermillion's pipeline."

Dr. Fung, age 39, is returning to the company after serving as Director of Clinical Research at Roche Molecular Systems. At Roche, he helped oversee a cervical cancer screening clinical trial involving 45,000 women. Dr. Fung originally joined Vermillion in May 2000 as a lead scientist in the newly formed Biomarker Discovery Centers. He was promoted to Vice President and Chief Scientific Officer in June 2006.

Prior to joining Vermillion, Dr. Fung was a Howard Hughes sponsored researcher at Stanford University. Dr. Fung has anatomic pathology training from Stanford Medical School and obtained his M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine. He graduated with a B.S. with honors from the California Institute of Technology. Dr. Fung has also held an Adjunct Assistant Professor position in the Department of Pathology at the Johns Hopkins University School of Medicine.

About the OVA1 Test

The OVA1 Test is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) -- and a proprietary algorithm to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.

The OVA1 Test is an aid to further assess the likelihood that malignancy is present when the physician's independent clinical and radiological evaluation does not indicate malignancy. The test should not be used without an independent clinical/radiological evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of the OVA1 Test carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.

Quest Diagnostics, which is a long-time investor in research and development of the OVA1 technology, has exclusive rights to offer the test to the clinical reference laboratory market in the U.S. for three years.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.

    Contact:

    Vermillion:
    Jill Totenberg
    The Totenberg Group
    Tel:  212 994 7363
    jtotenberg@totenberggroup.com

SOURCE Vermillion, Inc.


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... ... privately-held contract pharmaceutical development and manufacturing organisation, today announced the formation ... combining a leading CRO and the industry’s only Contract Commercial Organization (CCO). ...
(Date:12/6/2016)... Collins, Colorado (PRWEB) , ... December 06, 2016 ... ... of dynamic aqueous plasma technology platforms, announced today that the company has engaged ... Master Research and Development Agreement (MRDA) with the CSU Office of the Vice ...
(Date:12/6/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... of its previously-announced cash tender offers (the "Offers") ... accrued and unpaid interest to, but not including, ... expenses related to the Offers) (the "Maximum Tender ... table below (collectively, the "Notes"). The terms and ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... integration, and building management solutions headquartered in Aurora, Ohio, announced the opening of ... Springs, North Carolina, the newly constructed facility is home to 200 employees focused ...
Breaking Biology Technology:
(Date:12/5/2016)... -- The Office of Justice Programs, National Institute of ... or Replace Medico Legal Autopsies?" on NIJ.gov.  The ... forensic autopsies with postmortem X-ray computed tomography, commonly ... to recommendations made by The National Academy of ... a potential component of medicolegal death investigations. NIJ,s ...
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we spend ... recovery so we need to do it well. Inadequate sleep levels have been found ... pressure, stroke, diabetes, and even cancer. Maybe now is the best time ... could help them to manage their sleep quality? Continue ... ...
(Date:11/29/2016)... Nov. 29, 2016   Neurotechnology , ... object recognition technologies, today released FingerCell 3.0, ... recognition solutions that run on low-power, low-memory ... using less than 128KB of memory, enabling ... that have limited on-board resources, such as: ...
Breaking Biology News(10 mins):